-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since 2021, the overall research enthusiasm of the institution has exceeded that of last year
.
According to Wind data, in the first three quarters of 2021, 2,506 A-share companies have disclosed their investor relations activity records, a significant increase of more than 1,000 over the same period of the previous year
.
Judging from the number of "flops", in the first three quarters of 2021, about 362 A-share companies have received more than 100 institutional surveys, and 249 companies have been surveyed more than 100 times
.
Among them, Mindray Medical, a domestic medical device company, is more eye-catching
.
Wind data shows that in the first three quarters of this year, the number of Mindray medical reception institutions reached as high as 1,395
.
Recently, Mindray Medical has disclosed an "Investor Relations Activity Record".
The document shows that from August 30 to September 30, a total of 498 institutions have intensively investigated Mindray Medical.
The problem is the matter of centralized procurement and acquisition of sea peptide biology
.
Among them, in response to a document issued by the Anhui Provincial Pharmaceutical Centralized Procurement Service Center, it is necessary to implement centralized and large-scale procurement of chemiluminescence test reagents.
Mindray Medical responded to the current progress and stated that on August 27, the Anhui Provincial Pharmaceutical Centralized Procurement Service Center announced that the Anhui Provincial Public Medical As a result of the negotiation and bargaining for the centralized procurement of clinical test reagents in institutions, the company successfully shortlisted 14 chemiluminescence detection projects in this centralized negotiation
.
At the same time, the company stated that it will embrace policy changes and continue to make constant R&D investment to break through core key technologies while improving product cost-effectiveness
.
In addition, on the afternoon of September 29, the Nanjing Medical Insurance Bureau organized the Nanjing Medical Institution Alliance to conduct overall price negotiations with Mindray, which included in vitro diagnostic reagents and some orthopedic consumables, and the overall price reduction was 35.
51%
.
In this survey, Mindray Medical also responded to this matter
.
The company stated that, on the whole, this negotiation has been very positive for the company's IVD and orthopedics business to expand in the Nanjing market, but because the market size of a city is limited, the overall performance of the group is less affected.
.
Investors also expressed concern about Mindray Medical's 532 million euro acquisition of Haitide Bio, including the strategic significance of the acquisition for the company and the integration plan after the merger
.
The company replied that the acquisition of Haitide Bio will be of great significance to the company's in vitro diagnostic business
.
Mindray Medical will firmly support Haitide Bio to continuously increase R&D investment, and at the same time will integrate into the company's raw material R&D management team to establish a docking mechanism
.
Under the framework of legal compliance, through training, exchanges, joint development and other methods, the company's raw material research and development capabilities are enhanced to serve the company's long-term development strategy
.
According to data, Mindray Medical is a domestic high-tech medical equipment R&D and manufacturer.
Its main business covers life information and support, in vitro diagnostics, and medical imaging
.
Among them, the performance of the in vitro diagnostic business segment was outstanding
.
Mindray Medical's 2021 mid-year report shows that during the reporting period, the company's in vitro diagnostic business achieved operating income of 3.
962 billion yuan, a year-on-year increase of 30.
76%
.
It is worth mentioning that in the secondary market, Mindray Medical's share price has also climbed
.
According to statistics from Choice, in October, Mindray Medical will have 717 million IPO original shareholders' restricted shares due
.
However, under the influence of massive lifting of the ban and centralized procurement, Mindray Medical continues to be under tremendous pressure
.
As of the close on October 8, Mindray Medical reported 376 yuan, down 2.
35%, and its market value reached 457.
5 billion yuan
.
.
According to Wind data, in the first three quarters of 2021, 2,506 A-share companies have disclosed their investor relations activity records, a significant increase of more than 1,000 over the same period of the previous year
.
Judging from the number of "flops", in the first three quarters of 2021, about 362 A-share companies have received more than 100 institutional surveys, and 249 companies have been surveyed more than 100 times
.
Among them, Mindray Medical, a domestic medical device company, is more eye-catching
.
Wind data shows that in the first three quarters of this year, the number of Mindray medical reception institutions reached as high as 1,395
.
Recently, Mindray Medical has disclosed an "Investor Relations Activity Record".
The document shows that from August 30 to September 30, a total of 498 institutions have intensively investigated Mindray Medical.
The problem is the matter of centralized procurement and acquisition of sea peptide biology
.
Among them, in response to a document issued by the Anhui Provincial Pharmaceutical Centralized Procurement Service Center, it is necessary to implement centralized and large-scale procurement of chemiluminescence test reagents.
Mindray Medical responded to the current progress and stated that on August 27, the Anhui Provincial Pharmaceutical Centralized Procurement Service Center announced that the Anhui Provincial Public Medical As a result of the negotiation and bargaining for the centralized procurement of clinical test reagents in institutions, the company successfully shortlisted 14 chemiluminescence detection projects in this centralized negotiation
.
At the same time, the company stated that it will embrace policy changes and continue to make constant R&D investment to break through core key technologies while improving product cost-effectiveness
.
In addition, on the afternoon of September 29, the Nanjing Medical Insurance Bureau organized the Nanjing Medical Institution Alliance to conduct overall price negotiations with Mindray, which included in vitro diagnostic reagents and some orthopedic consumables, and the overall price reduction was 35.
51%
.
In this survey, Mindray Medical also responded to this matter
.
The company stated that, on the whole, this negotiation has been very positive for the company's IVD and orthopedics business to expand in the Nanjing market, but because the market size of a city is limited, the overall performance of the group is less affected.
.
Investors also expressed concern about Mindray Medical's 532 million euro acquisition of Haitide Bio, including the strategic significance of the acquisition for the company and the integration plan after the merger
.
The company replied that the acquisition of Haitide Bio will be of great significance to the company's in vitro diagnostic business
.
Mindray Medical will firmly support Haitide Bio to continuously increase R&D investment, and at the same time will integrate into the company's raw material R&D management team to establish a docking mechanism
.
Under the framework of legal compliance, through training, exchanges, joint development and other methods, the company's raw material research and development capabilities are enhanced to serve the company's long-term development strategy
.
According to data, Mindray Medical is a domestic high-tech medical equipment R&D and manufacturer.
Its main business covers life information and support, in vitro diagnostics, and medical imaging
.
Among them, the performance of the in vitro diagnostic business segment was outstanding
.
Mindray Medical's 2021 mid-year report shows that during the reporting period, the company's in vitro diagnostic business achieved operating income of 3.
962 billion yuan, a year-on-year increase of 30.
76%
.
It is worth mentioning that in the secondary market, Mindray Medical's share price has also climbed
.
According to statistics from Choice, in October, Mindray Medical will have 717 million IPO original shareholders' restricted shares due
.
However, under the influence of massive lifting of the ban and centralized procurement, Mindray Medical continues to be under tremendous pressure
.
As of the close on October 8, Mindray Medical reported 376 yuan, down 2.
35%, and its market value reached 457.
5 billion yuan
.
